Acute Effects of Cricket Fast Bowling on Bone Turnover and Signaling Markers

November 20, 2025 updated by: Katherine Brooke-Wavell, Loughborough University

The goal of this study is to investigate the acute effects of cricket fast bowling on the bone turnover and signaling markers in healthy young males.

The main question aims to answer:

• Does a single bout acute fast bowling change serum C-terminal telopeptide of type I collagen (CTX-I) and other bone turnover and signaling markers levels?

Participants complete both the bowling and control trials, with a minimum washout period of one week between trials. During each trial, blood samples are collected at three time points: pre-, immediately post, and 2-hour post bowling/rest.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Leicestershire
      • Loughborough, Leicestershire, United Kingdom, LE11 3TU
        • Loughborough Univeristy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy male
  • Aged 18 - 30
  • Cricket fast bowlers (a ball speed of ~100kmh) playing for a university team or above, such as British Universities and Colleges Sport (BUCS) or University Centre of Cricketing Excellence (UCCE)
  • Injury free for the last 3 months

Exclusion Criteria:

  • Diagnosed with any disease or use of any medication that affects bone turnover
  • Fracture experienced within the previous year/season

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm Bowling + Control
Participants first perform the bowling trial, followed by the control trial, with a minimum interval of one week between the two trials.
During the bowling trial, participants perform 8 sets of 6 deliveries (bowl at match intensity throughout), followed by 2-hour rest. Each set is interspersed by a 3-minute randomized fielding simulation. During the control trial, participants rest throughout instead of bowling.
Experimental: Arm Control + Bowling
Participants first perform the control trial, followed by the bowling trial, with a minimum interval of one week between the two trials.
During the bowling trial, participants perform 8 sets of 6 deliveries (bowl at match intensity throughout), followed by 2-hour rest. Each set is interspersed by a 3-minute randomized fielding simulation. During the control trial, participants rest throughout instead of bowling.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum C-terminal telopeptide of type I collagen (CTX-I) concentration
Time Frame: Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.
Serum CTX-I concentration is measured using electrochemiluminescence immunoassay (ECLIA) and reported in nanograms per milliliter (ng/mL).
Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum N-terminal propeptide of type I collagen (PINP) concentration
Time Frame: Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.
Serum PINP concentration is measured using electrochemiluminescence immunoassay (ECLIA) and reported in nanograms per milliliter (ng/mL).
Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.
Serum parathyroid hormone (PTH) concentration
Time Frame: Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.
Serum PTH concentration is measured using electrochemiluminescence immunoassay (ECLIA) and reported in picograms per milliliter (pg/mL).
Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.
Serum sclerostin concentration
Time Frame: Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.
Serum sclerostin concentration is measured using an enzyme-linked immunosorbent assay (ELISA) and reported in picograms per milliliter (pg/mL).
Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.
Serum dickkopf Wnt signaling pathway inhibitor 1 (DKK1) concentration
Time Frame: Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.
Serum DKK1 concentration is measured using an enzyme-linked immunosorbent assay (ELISA) and reported in picograms per milliliter (pg/mL).
Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.
Serum osteoprotegerin (OPG) concentration
Time Frame: Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.
Serum OPG concentration is measured using an enzyme-linked immunosorbent assay (ELISA) and reported in picograms per milliliter (pg/mL).
Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.
Serum irisin concentration
Time Frame: Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.
Serum irisin concentration is measured using an enzyme-linked immunosorbent assay (ELISA) and reported in picograms per milliliter (pg/mL).
Blood samples are collected at baseline, immediately after the bowling or the corresponding rest period, and 2 hours after the second blood sample collection.
Bowling speed
Time Frame: Bowling speed is measured during the bowling trial.
Bowling speed is measured using a radar gun during the 8 overs of bowling and reported in miles per hour (MPH).
Bowling speed is measured during the bowling trial.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Katherine Brooke-Wavell, Loughborough University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2023

Primary Completion (Estimated)

December 31, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

November 14, 2025

First Submitted That Met QC Criteria

November 20, 2025

First Posted (Estimated)

December 3, 2025

Study Record Updates

Last Update Posted (Estimated)

December 3, 2025

Last Update Submitted That Met QC Criteria

November 20, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Health Adults

Clinical Trials on Exercise

Subscribe